Market Overview
According to fortune business insights, the global sepsis diagnostics market size was valued at USD 1,003.95 million in 2025 and is projected to grow from USD 1,099.22 million in 2026 to USD 2,399.34 million by 2034, exhibiting a CAGR of 10.20% during the forecast period. North America dominated the sepsis diagnostics market with a market share of 51.50% in 2025.
Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Sepsis Diagnostics Market, 2026-2034.”
The analysis shows that the market is growing due to the rising prevalence of sepsis, a life-threatening condition affecting millions globally. Favorable reimbursement policies, various awareness programs, and strategic initiatives by key players to launch new products with advanced technologies are strongly contributing to the market's expansion.
Major Players Profiled in the Market Report:
- T2 Biosystems, Inc. (U.S.)
- Danaher (U.S.)
- Abbott (U.S.)
- bioMérieux SA (France)
- Thermo Fisher Scientific Inc. (U.S.)
- Luminex Corporation (DiaSorin S.p.A.) (U.S.)
- BD (Becton, Dickinson, and Company) (U.S.)
- Bruker (U.S.)
- Siemens Healthcare GmbH (Germany)
Segments
Reagents & Consumables to Dominate the Market Due to Robust Usage
Based on product type, the market is divided into reagents & consumables and instruments. The reagents & consumables segment is projected to lead the market with a 77.22% share in 2026, driven by their extensive and continuous use in diagnostic procedures.
Microbiology Technology to Lead Owing to Cost-Effectiveness
By technology, the market is categorized into microbiology, molecular diagnostics, immunoassays, and others. The microbiology segment is projected to dominate with a 58.85% share in 2026, as blood cultures and other cost-effective microbial tests are the standard of care in most hospitals.
Automated Method to Hold Largest Share Due to High Efficacy
Based on method, the market is segmented into conventional and automated. The automated segment is expected to lead with a 93.26% share in 2026, owing to its high efficacy, specificity, and the increasing launch of new, advanced automated systems by key players.
Bacterial Pathogen Segment to Dominate Due to High Incidence
By pathogen, the market is divided into bacterial, fungal, and others. The bacterial segment is projected to generate the highest market share, as bacterial infections are the most common cause of sepsis, driving the demand for specific diagnostic tests.
Hospitals & Clinics to Dominate End-User Segment
Based on end user, the market is segmented into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment dominates the market as sepsis patients are usually treated in ICUs, where most diagnostic tests are performed.
For detailed market insights: https://www.fortunebusinessinsights.com/sepsis-diagnostics-market-107417
Report Coverage
The report offers:
- Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
- Comprehensive insights into regional developments.
- List of major industry players.
- Key industry developments, new product launches, and technological advancements.
- The latest regulatory and reimbursement scenarios, and the impact of COVID-19.
Drivers & Restraints
Rising Incidence of Sepsis Globally to Propel Market Growth
The primary driver for the market is the rising global incidence of sepsis. The increasing number of cases, particularly among hospitalized patients, has led to a strong demand for effective and rapid diagnostic measures to improve patient outcomes and reduce mortality rates.
Improvement in Awareness in Emerging Countries
Another key driver is the improvement in awareness in developing nations. Numerous government and non-government bodies are implementing programs to improve screening, education, and the adoption of advanced diagnostics, which is expected to augment market growth.
However, the prohibitively expensive cost of diagnostic devices and tests may restrain market growth. The high cost associated with diagnosing and treating sepsis creates a financial burden for patients and healthcare systems, potentially limiting the adoption of these advanced diagnostic solutions, especially in emerging economies.
Regional Insights
Strong Adoption of Advanced Diagnostics Propels Market Growth in North America
North America holds the dominant sepsis diagnostics market share, accounting for 51.50% in 2025. The region’s growth is attributed to the high incidence of sepsis, rapid adoption of advanced diagnostics, and favorable reimbursement policies, particularly in the U.S.
Europe is the second-leading region, driven by an increasing number of diagnostic procedures, a growing number of skilled professionals, and regulatory approvals for advanced diagnostic instruments. The Asia Pacific market is expected to develop significantly, fueled by increasing awareness, the development of clinical guidelines, and new product launches in the region.
Sepsis Diagnostics Market Trends:
A prominent trend in the global market is the rising adoption of rapid diagnostic or Point-of-Care (POC) techniques for the early diagnosis of sepsis. Key companies are increasingly focused on developing these systems, which significantly improve the speed, standardization, and efficacy of sepsis diagnostics. These techniques offer rapid and reliable results with the need for fewer skilled healthcare professionals. This focus on launching new products with advanced POC technologies, such as Inflammatix's TriVerity system, is expected to be instrumental in the market's future growth.
Competitive Landscape
Diversified Portfolios and Strategic Initiatives to Propel Market Growth
The market depicts a fairly fragmented structure, with leading players such as bioMérieux SA, Danaher, Thermo Fisher Scientific Inc., and BD holding strong positions due to their diversified diagnostic portfolios and established geographical presence. These companies are accelerating growth through advanced product launches and strategic partnerships. Emerging players are strengthening their market position through geographical expansion and territory-exclusive distribution agreements, intensifying competition and innovation.
Key Industry Development
- November 2023: The University of Oxford partnered with Danaher Corporation to develop a new test to enable precision medicine care for sepsis.
- November 2023: Oxford Nanopore Technologies collaborated with Day Zero Diagnostics to develop an end-to-end diagnostic solution for bloodstream infections.
- May 2022: bioMérieux SA received approval from Health Canada for its BIOFIRE Blood Culture Identification 2 (BCID2) Panel, a rapid molecular diagnostic for bloodstream infections.
Uncover Japan’s Market Trends - Explore the Latest Sepsis Diagnostics Market Insights
Comments